Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience

被引:23
作者
Briggs, Elissa Charlotte [1 ]
Thuan Nguyen [1 ]
Wall, Michael Abraham [1 ]
MacDonald, Kelvin David [1 ]
机构
[1] Oregon Hlth & Sci Univ, CDRCP, Portland, OR 97239 USA
关键词
antibiotics; cystic fibrosis; exacerbation; pneumonia; RESISTANT STAPHYLOCOCCUS-AUREUS; CIPROFLOXACIN THERAPY; ANTIBIOTIC-TREATMENT; LUNG-DISEASE; INFECTIONS; EPIDEMIOLOGY; ASSOCIATION; EFFICACY; CHILDREN; FEV1;
D O I
10.1111/j.1752-699X.2011.00246.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Cystic fibrosis (CF) pulmonary disease is characterized by intermittent episodes of acute lung symptoms known as pulmonary exacerbations. While exacerbations are classically treated with parenteral antimicrobials, oral antibiotics are often used in mild cases. Objectives: We determined how often management progressed to intravenous (IV) therapy. We also examined multiple courses of oral antimicrobials within one exacerbation, and identified patient factors associated with unsuccessful treatment. Methods: We performed a retrospective chart audit of oral antibiotic use in CF patients, from March 2009 through March 2010, for 'mild' CF exacerbations. Results: Administration of a single vs multiple courses of oral antibiotics for treatment of 'mild' CF exacerbation avoided progression to IV therapy 79.8% and 50.0% of the time, respectively. Overall, oral antibiotics circumvented the need for IV therapy 73.8% of the time. Using multi-variant analysis, we found multiple patient characteristics to be independent risk factors for oral antibiotic failure including a history of pseudomonas infection [odds ratio (OR) 2.13, confidence interval (CI) 1.29-3.54], CF-related diabetes (OR 1.85, CI 1.00-3.41), allergic Bronchopulmonary aspergillosis (OR 3.81, CI 1.38-10.56), low socioeconomic status (OR 1.67, CI 1.04-2.67), and calculated baseline forced expiratory volume in 1 s (FEV1) < 75% of predicted prior to an acute exacerbation (OR 1.93, CI 1.20-3.08). Decline in FEV1 > 10%, weight for age, body mass index, distance from the CF center and gender were not significant. Conclusion: Our observations suggest that one course of oral antimicrobials is frequently effective in outpatient CF pulmonary exacerbations but exacerbations requiring more than one course of oral antibiotics are likely to require IV therapy.
引用
收藏
页码:56 / 64
页数:9
相关论文
共 29 条
[1]   Allergic Bronchopulmonary Aspergillosis [J].
Agarwal, Ritesh .
CHEST, 2009, 135 (03) :805-826
[2]   Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria [J].
Block, J. K. ;
Vandemheen, K. L. ;
Tullis, E. ;
Fergusson, D. ;
Doucette, S. ;
Haase, D. ;
Berthiaume, Y. ;
Brown, N. ;
Wilcox, P. ;
Bye, P. ;
Bell, S. ;
Noseworthy, M. ;
Pedder, L. ;
Freitag, A. ;
Paterson, N. ;
Aaron, S. D. .
THORAX, 2006, 61 (11) :969-974
[3]   Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis [J].
Britto, MT ;
Kotagal, UR ;
Hornung, RW ;
Atherton, HD ;
Tsevat, J ;
Wilmott, RW .
CHEST, 2002, 121 (01) :64-72
[4]   Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis [J].
Dasenbrook, Elliott C. ;
Merlo, Christian A. ;
Diener-West, Marie ;
Lechtzin, Noah ;
Boyle, Michael P. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (08) :814-821
[5]   Association Between Respiratory Tract Methicillin-Resistant Staphylococcus aureus and Survival in Cystic Fibrosis [J].
Dasenbrook, Elliott C. ;
Checkley, William ;
Merlo, Christian A. ;
Konstan, Michael W. ;
Lechtzin, Noah ;
Boyle, Michael P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (23) :2386-2392
[6]   Genetic modifiers of lung disease in cystic fibrosis [J].
Drumm, ML ;
Konstan, MW ;
Schluchter, MD ;
Handler, A ;
Pace, R ;
Zou, F ;
Zariwala, M ;
Fargo, D ;
Xu, AR ;
Dunn, JM ;
Darrah, RJ ;
Dorfman, R ;
Sandford, AJ ;
Corey, M ;
Zielenski, J ;
Durie, P ;
Goddard, K ;
Yankaskas, JR ;
Wright, FA ;
Knowles, MR .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (14) :1443-1453
[7]   THE CHANGING EPIDEMIOLOGY OF CYSTIC-FIBROSIS [J].
FITZSIMMONS, SC .
JOURNAL OF PEDIATRICS, 1993, 122 (01) :1-9
[8]   Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations [J].
Flume, Patrick A. ;
Mogayzel, Peter J., Jr. ;
Robinson, Karen A. ;
Goss, Christopher H. ;
Rosenblatt, Randall L. ;
Kuhn, Robert J. ;
Marshall, Bruce C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (09) :802-808
[9]   Pathophysiology and management of pulmonary infections in cystic fibrosis [J].
Gibson, RL ;
Burns, JL ;
Ramsey, BW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (08) :918-951
[10]   Exacerbations in cystic fibrosis •1:: Epidemiology and pathogenesis [J].
Goss, Christopher H. ;
Burns, Jane L. .
THORAX, 2007, 62 (04) :360-367